Elevated Testosterone Does NOT Increase Prostate Cancer Risk
No compelling evidence exists that elevated testosterone levels—whether endogenous or from testosterone replacement therapy—increase the risk of developing prostate cancer. 1
The Evidence Against the Testosterone-Prostate Cancer Link
Endogenous Testosterone Studies
Multiple prospective studies examining naturally occurring testosterone levels have failed to demonstrate a causative relationship:
Prospective cohort data from stored frozen plasma samples showed no difference in testosterone levels between men who developed prostate cancer 7-25 years later and those who did not 1
A comprehensive 2001 review by Hsing of 12 prospective studies found only one study (the Physicians' Health Study) suggesting any association, but even this study showed no significant difference in mean testosterone levels between prostate cancer patients and controls, and no difference in cancer risk between men in the highest versus lowest testosterone quartiles 1
A 2016 meta-analysis of 20 estimates produced a summary relative risk of 0.99 (95% CI 0.96-1.02) for prostate cancer per 5 nmol/L increase in testosterone—essentially no association 2
Testosterone Replacement Therapy Safety
The evidence from clinical trials is equally reassuring:
The TRAVERSE trial (2025)—the most recent and highest quality evidence—confirmed no difference in prostate cancer incidence between testosterone and placebo groups at mean follow-up of 33 months 3
A meta-analysis of 11 testosterone replacement trials showed a summary relative risk of prostate cancer of 0.87 (95% CI 0.30-2.50)—if anything, a trend toward lower risk 2
Multiple prospective trials spanning 6-36 months found only 5 cases of prostate cancer among 461 men (1.1%) receiving testosterone therapy—similar to the general population rate 1
PSA levels increased by only 0.10 ng/mL overall after testosterone therapy initiation—a clinically insignificant change 2
The Critical Paradox
Prostate cancer becomes more prevalent exactly when testosterone levels decline with aging 1. This temporal relationship directly contradicts the hypothesis that higher testosterone drives cancer development.
Understanding the Saturation Model
The key to understanding testosterone's relationship with prostate tissue is the concept of androgen adequacy versus inadequacy 4:
- Prostate cells require adequate testosterone for normal function, but growth reaches a saturation point at relatively low testosterone concentrations
- Above this saturation point, additional testosterone does not further stimulate growth
- Below this point, cellular metabolism is compromised
- This explains why androgen deprivation therapy works for existing cancer (by creating severe inadequacy) but higher normal-range testosterone doesn't cause cancer
Important Caveats and Monitoring
Testosterone Can Unmask Existing Cancer
While testosterone doesn't cause prostate cancer, it may promote growth of pre-existing occult disease:
- One study found 14% of hypogonadal men with normal PSA and digital rectal exam had occult prostate cancer on baseline biopsy 1
- Case reports describe cancers becoming clinically apparent within months of starting testosterone therapy 5
- This represents unmasking of existing disease, not causation of new cancer
Mandatory Screening Protocol
Before initiating testosterone therapy 1:
- Baseline PSA and digital rectal examination are mandatory
- Perform prostate biopsy if PSA >4.0 ng/mL or abnormal digital rectal exam
- Consider lower PSA threshold (2.6-4.0 ng/mL) in higher-risk patients
Ongoing Monitoring Requirements
During testosterone therapy 1:
- PSA, digital rectal exam, and testosterone levels every 3-6 months for the first year, then annually
- Low threshold for biopsy if:
- PSA rises above 4.0 ng/mL
- PSA increases >1.5 ng/mL/year
- PSA increases >0.75 ng/mL/year over 2 years
- Digital rectal exam shows new nodule, asymmetry, or increased firmness
Contradictory Evidence to Address
Two older studies suggested possible associations that deserve mention:
- A 2005 Baltimore Longitudinal Study found higher calculated free testosterone associated with increased prostate cancer risk (RR 2.59 for highest quartile) 6
- A 2010 follow-up from the same cohort found doubled risk of high-risk disease in men >65 years with higher free testosterone index 7
However, these findings:
- Conflict with the larger body of prospective evidence
- Were not replicated in the comprehensive 2016 meta-analysis 2
- Predate the definitive TRAVERSE trial 3
- Used complex statistical adjustments of uncertain clinical significance
The weight of evidence, particularly the most recent high-quality guideline data, does not support restricting testosterone therapy based on cancer risk in appropriately screened men.
Clinical Bottom Line
Elevated testosterone—whether naturally occurring or from replacement therapy—does not increase prostate cancer risk when proper screening excludes pre-existing disease. The historical prohibition against testosterone therapy was based on flawed assumptions. Testosterone therapy is safe in appropriately selected and monitored hypogonadal men, including those with treated prostate cancer in select circumstances 3, 8, 9.